115 related articles for article (PubMed ID: 26411398)
1. Cancer Drugs Fund failed to collect patient outcomes.
Baker H
Lancet Oncol; 2015 Nov; 16(15):e529. PubMed ID: 26411398
[No Abstract] [Full Text] [Related]
2. MPs find no evidence that Cancer Drugs Fund was spent wisely.
Hawkes N
BMJ; 2016 Feb; 352():i755. PubMed ID: 26850036
[No Abstract] [Full Text] [Related]
3. Reforming the cancer drug fund.
Buxton M; Longworth L; Raftery J; Sculpher M; Towse A
BMJ; 2014 Nov; 349():g7276. PubMed ID: 25432928
[No Abstract] [Full Text] [Related]
4. New Cancer Drugs Fund solves the wrong problem.
Hatswell AJ
BMJ; 2016 Oct; 355():i5619. PubMed ID: 27784653
[No Abstract] [Full Text] [Related]
5. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
Mayor S
BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
[No Abstract] [Full Text] [Related]
6. Challenges for the new Cancer Drugs Fund.
Littlejohns P; Weale A; Kieslich K; Wilson J; Rumbold B; Max C; Rid A
Lancet Oncol; 2016 Apr; 17(4):416-418. PubMed ID: 26948924
[No Abstract] [Full Text] [Related]
7. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V; Mailankody S
Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
[No Abstract] [Full Text] [Related]
8. Conservatism and the cancer drugs fund.
Hopkinson NS
BMJ; 2017 May; 357():j2451. PubMed ID: 28539426
[No Abstract] [Full Text] [Related]
9. NHS will not pay for drugs that offer little clinical benefit, says cancer fund boss.
Kmietowicz Z
BMJ; 2015 Jan; 350():h125. PubMed ID: 25569117
[No Abstract] [Full Text] [Related]
10. Investment fund established to combat cancer drug 'development gap'.
Hemsley A
Future Med Chem; 2012 May; 4(8):948. PubMed ID: 22826901
[No Abstract] [Full Text] [Related]
11. Sixty seconds on . . . the Cancer Drugs Fund.
Hawkes N
BMJ; 2016 Feb; 352():i791. PubMed ID: 26860994
[No Abstract] [Full Text] [Related]
12. UK Cancer Drugs Fund to reassess 42 agents.
Cagney H
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638560
[No Abstract] [Full Text] [Related]
13. Treatment. Dramatic licence.
Bryan J
Health Serv J; 2000 Apr; 110(5702):suppl 6-7. PubMed ID: 11183034
[No Abstract] [Full Text] [Related]
14. Cancer drugs: swallowing big pharma's line?
Coombes R
BMJ; 2007 May; 334(7602):1034-5. PubMed ID: 17510150
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in patients with recurrent/progressive glioblastoma treated with bevacizumab funded by a regional cancer drug fund.
Dixit S; Hatfield P; Clenton S; Loughrey C; Hingorani M
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):238-9. PubMed ID: 24461951
[No Abstract] [Full Text] [Related]
16. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
Leigh S; Granby P
Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
[TBL] [Abstract][Full Text] [Related]
17. Clinical management. On living with cancer.
Thomas H
Health Serv J; 2006 Jul; 116(6014):27. PubMed ID: 16884040
[No Abstract] [Full Text] [Related]
18. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group workshop. Improvements in patient access to new anti-cancer medicines.
Br J Cancer; 1999 Jan; 79(1):2-3. PubMed ID: 10408683
[No Abstract] [Full Text] [Related]
19. UK cancer fund finds new ways of making money.
McGourty C
Nature; 1989 Apr; 338(6218):695. PubMed ID: 2716816
[No Abstract] [Full Text] [Related]
20. NICE and the Cancer Drugs Fund--2020 vision?
Drug Ther Bull; 2016 Apr; 54(4):37. PubMed ID: 27056193
[No Abstract] [Full Text] [Related]
[Next] [New Search]
